Accelerating Diversity Enrollment in a Phase III COVID-19 Clinical Trial
Use Case
Patient Engagement & Recruitment
As the world watched with anticipation, a biotechnology company’s COVID-19 Phase III clinical trial inched closer to its target enrollment of 30,000 participants but was falling short on inclusion of participants historically underrepresented in clinical trials and disproportionately impacted by COVID-19. The sponsor partnered with Citeline Connect to rapidly fill the enrollment gap.
